(1) Background: Cognitive deterioration is an important marker of disease activity in multiple sclerosis (MS). It is vital to detect cognitive decline as soon as possible. Cognitive deterioration can take the form of isolated cognitive decline (ICD) with no other clinical signs of disease progression present. (2) Methods: We investigated 1091 MS patients from the longitudinal GQ (Grant Quantitative) study, assessing their radiological, neurological, and neuropsychological data. Additionally, the confirmatory analysis was conducted. Clinical disease activity was defined as the presence of new relapse or disability worsening. MRI activity was defined as the presence of new or enlarged T2 lesions on brain MRI. (3) Results: Overall, 6.4% of patients experienced cognitive decline and 4.0% experienced ICD without corresponding clinical activity. The vast majority of cognitively worsening patients showed concomitant progression in other neurological and radiologic measures. There were no differences in disease severity between completely stable patients and cognitively worsening patients but with normal cognition at baseline. (4) Conclusions: Only a small proportion of MS patients experience ICD over short-term follow-up. Patients with severe MS are more prone to cognitive decline; however, patients with normal cognitive performance and mild MS might benefit from the early detection of cognitive decline the most.

Buffalo Neuroimaging Analysis Center Department of Neurology Jacobs School of Medicine and Biomedical Sciences University at Buffalo State University of New York Buffalo NY 14203 USA

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine and General University Hospital Charles University Prague 128 21 Prague Czech Republic

Department of Radiology 1st Faculty of Medicine and General University Hospital Prague Charles University Prague 128 08 Prague Czech Republic

Zobrazit více v PubMed

Benedict R.H.B., Amato M.P., DeLuca J., Geurts J.J.G. Cognitive impairment in multiple sclerosis: Clinical management, MRI, and therapeutic avenues. Lancet Neurol. 2020;19:860–871. doi: 10.1016/S1474-4422(20)30277-5. PubMed DOI PMC

Kalb R., Beier M., Benedict R.H.B., Charvet L., Costello K., Feinstein A., Gingold J., Goverover Y., Halper J., Harris C., et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult. Scler. J. 2018;24:1665–1680. doi: 10.1177/1352458518803785. PubMed DOI PMC

Sumowski J.F., Benedict R., Enzinger C., Filippi M., Geurts J.J., Hamalainen P., Hulst H., Inglese M., Leavitt V.M., Rocca M.A., et al. Cognition in multiple sclerosis: State of the field and priorities for the future. Neurology. 2018;90:278–288. doi: 10.1212/WNL.0000000000004977. PubMed DOI PMC

Benedict R.H.B., Pol J., Yasin F., Hojnacki D., Kolb C., Eckert S., Tacca B., Drake A., Wojcik C., Morrow S.A., et al. Recovery of cognitive function after relapse in multiple sclerosis. Mult. Scler. J. 2020:1–8. doi: 10.1177/1352458519898108. PubMed DOI

Portaccio E., Stromillo M.L., Goretti B., Zipoli V., Siracusa G., Battaglini M., Giorgio A., Bartolozzi M.L., Guidi L., Sorbi S., et al. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology. 2009;73:498–503. doi: 10.1212/WNL.0b013e3181b351fd. PubMed DOI

Damasceno A., Damasceno B.P., Cendes F. No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy. Mult. Scler. J. 2016;22:64–72. doi: 10.1177/1352458515604383. PubMed DOI

Pardini M., Uccelli A., Grafman J., Yaldizli Ö., Mancardi G., Roccatagliata L. Isolated cognitive relapses in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2014;85:1035–1037. doi: 10.1136/jnnp-2013-307275. PubMed DOI

Weinstock-Guttman B., Eckert S., Benedict R.H. A decline in cognitive function should lead to a change in disease-modifying therapy—Yes. Mult. Scler. J. 2018;24:1681–1682. doi: 10.1177/1352458518783364. PubMed DOI

Portaccio E. A decline in cognitive function should lead to a change in disease-modifying therapy—No. Mult. Scler. J. 2018;24:1683–1684. doi: 10.1177/1352458518783357. PubMed DOI

Di Filippo M., Portaccio E., Mancini A., Calabresi P. Multiple sclerosis and cognition: Synaptic failure and network dysfunction. Nat. Rev. Neurosci. 2018;19:599–609. doi: 10.1038/s41583-018-0053-9. PubMed DOI

Eijlers A.J.C., Meijer K.A., Van Geest Q., Geurts J.J.G., Schoonheim M.M. Determinants of cognitive impairment in patients with multiple sclerosis with and without atrophy. Radiology. 2018;288:544–551. doi: 10.1148/radiol.2018172808. PubMed DOI

Johnen A., Schiffler P., Landmeyer N.C., Tenberge J.G., Riepl E., Wiendl H., Krämer J., Meuth S.G. Resolving the cognitive clinico-radiological paradox—Microstructural degeneration of fronto-striatal-thalamic loops in early active multiple sclerosis. Cortex. 2019;121:239–252. doi: 10.1016/j.cortex.2019.08.022. PubMed DOI

Steenwijk M.D., Geurts J.J.G., Daams M., Tijms B.M., Wink A.M., Balk L.J., Tewarie P.K., Uitdehaag B.M.J., Barkhof F., Vrenken H., et al. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. Brain. 2016;139:115–126. doi: 10.1093/brain/awv337. PubMed DOI

Meli R., Roccatagliata L., Capello E., Bruschi N., Uccelli A., Mancardi G., Inglese M., Pardini M. Ecological impact of isolated cognitive relapses in MS. Mult. Scler. J. 2018:1–4. doi: 10.1177/1352458518813722. PubMed DOI

Uher T., Vaneckova M., Sormani M.P., Krasensky J., Sobisek L., Dusankova J.B., Seidl Z., Havrdova E., Kalincik T., Benedict R.H.B.B., et al. Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach. Eur. J. Neurol. 2017;24:292–301. doi: 10.1111/ene.13200. PubMed DOI

Uher T., Krasensky J., Sobisek L., Blahova Dusankova J., Seidl Z., Kubala Havrdova E., Sormani M.P., Horakova D., Kalincik T., Vaneckova M. Cognitive clinico-radiological paradox in early stages of multiple sclerosis. Ann. Clin. Transl. Neurol. 2018;5:81–91. doi: 10.1002/acn3.512. PubMed DOI PMC

Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi G., Correale J., Fazekas F., Filippi M., Freedman M.S., et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–173. doi: 10.1016/S1474-4422(17)30470-2. PubMed DOI

Uher T., Krasensky J., Vaneckova M., Sobisek L., Seidl Z., Havrdova E., Bergsland N., Dwyer M.G., Horakova D., Zivadinov R. A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study. J. Neuroimaging. 2017;27:620–629. doi: 10.1111/jon.12445. PubMed DOI

Blahova Dusankova J., Kalincik T., Havrdova E., Benedict R.H.B. Cross cultural validation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) and the brief international cognitive assessment for multiple sclerosis (BICAMS) Clin. Neuropsychol. 2012;26:1186–1200. doi: 10.1080/13854046.2012.725101. PubMed DOI

Benedict R.H., Amato M.P., Boringa J., Brochet B., Foley F., Fredrikson S., Hamalainen P., Hartung H., Krupp L., Penner I., et al. Brief International Cognitive Assessment for MS (BICAMS): International standards for validation. BMC Neurol. 2012;12:55. doi: 10.1186/1471-2377-12-55. PubMed DOI PMC

Rao S.M., Cognitive Function Study Group of the National Multiple Sclerosis Society . A Manual for the Brief, Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. National Multiple Sclerosis Society; New York, NY, USA: 1990.

Smith A. Symbol Digit Modalities Test [Manual] Western Psychological Services; Torrance, CA, USA: 1973.

Beck A.T., Steer R.A., Carbin M.G. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin. Psychol. Rev. 1988;8:77–100. doi: 10.1016/0272-7358(88)90050-5. DOI

Lord F.M., Novick M.R. Statistical Theories of Mental Test Scores. Addison-Wesley Publishing; London, UK: 1968.

Cígler H., Šmíra M. Chyba měření a odhad pravého skóru: Připomenutí některých postupů Klasické testové teorie. Testfórum. 2015;4:67–84. doi: 10.5817/TF2015-6-104. DOI

Jacobson N.S., Truax P. Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. J. Consult. Clin. Psychol. 1991;59:12–19. doi: 10.1037/0022-006X.59.1.12. PubMed DOI

Eijlers A.J.C., van Geest Q., Dekker I., Steenwijk M.D., Meijer K.A., Hulst H.E., Barkhof F., Uitdehaag B.M.J., Schoonheim M.M., Geurts J.J.G. Predicting cognitive decline in multiple sclerosis: A 5-year follow-up study. Brain. 2018:2605–2618. doi: 10.1093/brain/awy202. PubMed DOI

Strober L., DeLuca J., Benedict R.H., Jacobs A., Cohen J.A., Chiaravalloti N., Hudson L.D., Rudick R.A., LaRocca N.G. Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis. Mult. Scler. J. 2019;25:1781–1790. doi: 10.1177/1352458518808204. PubMed DOI PMC

Foley F.W., Benedict R.H.B., Gromisch E.S., DeLuca J. The Need for Screening, Assessment, and Treatment for Cognitive Dysfunction in Multiple Sclerosis. Int. J. MS Care. 2012;14:58–64. doi: 10.7224/1537-2073-14.2.58. PubMed DOI PMC

Morrow S.A., Drake A., Zivadinov R., Munschauer F., Weinstock-Guttman B., Benedict R.H.B. Predicting loss of employment over three years in multiple sclerosis: Clinically meaningful cognitive decline. Clin. Neuropsychol. 2010;24:1131–1145. doi: 10.1080/13854046.2010.511272. PubMed DOI

Benedict R.H.B., DeLuca J., Phillips G., LaRocca N., Hudson L.D., Rudick R. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Mult. Scler. J. 2017;23:721–733. doi: 10.1177/1352458517690821. PubMed DOI PMC

Uher T., Blahova-Dusankova J., Horakova D., Bergsland N., Tyblova M., Benedict R.H.B., Kalincik T., Ramasamy D.P., Seidl Z., Hagermeier J., et al. Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. J. Neurol. 2014;261:1735–1744. doi: 10.1007/s00415-014-7413-9. PubMed DOI

Cortese M., Riise T., Bjørnevik K., Bhan A., Farbu E., Grytten N., Hogenesch I., Midgard R., Smith Simonsen C., Telstad W., et al. Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom. Ann. Neurol. 2016;80:616–624. doi: 10.1002/ana.24769. PubMed DOI

Saccà F., Costabile T., Carotenuto A., Lanzillo R., Moccia M., Pane C., Russo C.V., Barbarulo A.M., Casertano S., Rossi F., et al. The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests. Mult. Scler. J. 2017;23:1289–1296. doi: 10.1177/1352458516677592. PubMed DOI

Rocca M.A., Amato M.P., De Stefano N., Enzinger C., Geurts J.J., Penner I.K., Rovira A., Sumowski J.F., Valsasina P., Filippi M. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol. 2015;14:302–317. doi: 10.1016/S1474-4422(14)70250-9. PubMed DOI

Gill S., Santo J., Blair M., Morrow S.A. Depressive Symptoms Are Associated with More Negative Functional Outcomes Than Anxiety Symptoms in Persons with Multiple Sclerosis. J. Neuropsychiatry Clin. Neurosci. 2019;31:37–42. doi: 10.1176/appi.neuropsych.18010011. PubMed DOI

Attix D.K., Story T.J., Chelune G.J., Ball J.D., Stutts M.L., Hart R.P., Barth J.T. The prediction of change: Normative neuropsychological trajectories. Clin. Neuropsychol. 2009;23:21–38. doi: 10.1080/13854040801945078. PubMed DOI

Sormani M.P., De Stefano N., Giovannoni G., Langdon D., Piani-Meier D., Haering D.A., Kappos L., Tomic D. Learning ability correlates with brain atrophy and disability progression in RRMS. J. Neurol. Neurosurg. Psychiatry. 2019;90:38–43. doi: 10.1136/jnnp-2018-319129. PubMed DOI PMC

Rhodes J.K., Schindler D., Rao S.M., Venegas F., Bruzik E.T., Gabel W., Williams J.R., Phillips G.A., Mullen C.C., Freiburger J.L., et al. Multiple Sclerosis Performance Test: Technical Development and Usability. Adv. Ther. 2019;36:1741–1755. doi: 10.1007/s12325-019-00958-x. PubMed DOI PMC

Friedova L., Rusz J., Motyl J., Srpova B., Vodehnalova K., Andelova M., Novotna K., Novotny M., Ruzickova H., Tykalova T., et al. Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: A pilot study. J. Clin. Neurosci. 2019;65:28–33. doi: 10.1016/j.jocn.2019.04.018. PubMed DOI

Ziemssen T., Kern R., Thomas K. Multiple sclerosis: Clinical profiling and data collection as prerequisite for personalized medicine approach. BMC Neurol. 2016;16:1–10. doi: 10.1186/s12883-016-0639-7. PubMed DOI PMC

Lexical and syntactic deficits analyzed via automated natural language processing: the new monitoring tool in multiple sclerosis